Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

India Sovaldi Opposition Hearing Ends; EU Case Looms

This article was originally published in Scrip

Executive Summary

US-based not-for-profit group Initiative for Medicines, Access and Knowledge (I-MAK) believes that China's decision rejecting Gilead Sciences' patent application for sofosbuvir could buttress its Indian opposition case against the patent claim for the blockbuster hepatitis C therapy.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register